By Dean Seal

Editas Medicine has agreed to license Vertex Pharmaceuticals its Cas9 gene editing technology for ex vivo gene editing medicines targeted at sickle cell disease and beta thalassemia.

The clinical-stage genome editing company said Wednesday that under the terms of the agreement, Vertex will obtain a non-exclusive license for the technology in medicines targeting the BCL11A gene in the fields of sickle cell disease and beta thalassemia, which includes the cell-based gene therapy Casgevy.

The deal extends Editas' cash runway into 2026, the company said, though it didn't disclose the financial terms of the agreement.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

December 13, 2023 09:34 ET (14:34 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Editas Medicine (NASDAQ:EDIT)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Editas Medicine 차트를 더 보려면 여기를 클릭.
Editas Medicine (NASDAQ:EDIT)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Editas Medicine 차트를 더 보려면 여기를 클릭.